Adult in Medical Technology

World's First Cardiac Adult Stem Cell Patient Receives Infusion

Trial taking place in Louisville, KY LOUISVILLE, Ky., July 24 /PRNewswire-USNewswire/ -- Michael (Mike) Jones has become the world's first recipient of adult cardiac stem cells to treat congestive heart failure. Jones' infusion on July 17 marks the world's first phase-one...

ASMANEX(R) (Mometasone Furoate Dry Powder Inhaler) Now Approved in Japan for the Treatment of Bronchial Asthma in Adult Patients

KENILWORTH, N.J., July 9 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP ) today announced that Schering-Plough K.K., the company's country operation in Japan, has received marketing approval for ASMANEX TWISTHALER (mometasone furoate dry powder inhaler) for the treatment of bro...

Long-term Follow Up Interim Data Show Nplate(TM) Increased and Sustained Platelet Counts in Adult Chronic ITP Patients

SAN FRANCISCO, Dec. 8 /PRNewswire-FirstCall/ -- Amgen Inc. (Nasdaq: AMGN ) today released updated results from the ongoing, open-label extension study of the long-term safety and efficacy of Nplate(TM) (romiplostim) in adult patients with chronic immune thrombocytopenic purpura (ITP). Chronic IT...

Technique for Rapidly Reprogramming Adult Cells Into Stem Cells Published in PLoS Biology

- Technology In-Licensed by Stem Cell Sciences From University of Cambridge - ("Stem Cell Sciences", "SCS", "the Company") CAMBRIDGE, England, Oct. 24 /PRNewswire/ -- Stem Cell Sciences plc (AIM: STEM, ASX: STC), a company focused on the commercialisation of stem cells and stem cell ...

Novexel Reports Positive Phase II Trial Results With NXL103 in Adult Patients With Community Acquired Pneumonia

PARIS, October 23 /PRNewswire/ -- Novexel, a speciality pharmaceutical company focused on the discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance, announces positive results from its Phase II clinical trial evaluating NXL10...

Video: The Looming Crisis in Cancer Drug Development: 97% of Adult Cancer Patients Do Not Take Advantage of Clinical Trial Programs

American Association for Cancer Research Aims to Raise Awareness about the Importance of Clinical Trial Participation PHILADELPHIA, Sept. 24 /PRNewswire/ -- News facts: -- Most Americans with cancer would be receptive to participating in clinical trials if they knew about them. ...

New Data Support Role for Monitoring of Cell-Mediated Immunity in Adult Patients Following Renal Transplantation

Cylex's ImmuKnow(R) assay shows clinical potential in independent study of adult kidney transplant patients COLUMBIA, Md., Aug. 21 /PRNewswire/ -- A recently published article by Sanchez-Velasco et al.* in Clinical Transplantation has expanded our understanding of the clinica...

Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients

Data Show Encouraging Results for a Potential New Front-Line Treatment Approach in AML CAMBRIDGE, Mass., June 2 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ ) reported preliminary data today from a fully-enrolled pivotal, phase 2 study examining the safety...

Abbott Presents Long-Term Data From Extension Study Showing Adult Crohn's Patients Treated With HUMIRA(R) (Adalimumab) Maintained Remission

Three of Four HUMIRA Patients from CHARM Study in Remission at One Year Maintained Remission at Two Years ABBOTT PARK, Ill., May 21 /PRNewswire-FirstCall/ -- Results from an open-label extension study of two Abbott pivotal studies, CHARM and GAIN, demonstrate that adult moder...

New AMITIZA 8 mcg Phase III Studies Demonstrated Overall Symptom Improvement in Adult Women with Irritable Bowel Syndrome with Constipation (IBS-C)

Additional Digestive Disease Week data highlight effects of AMITIZA in patients with IBS-C SAN DIEGO, May 18 /PRNewswire/ -- New study results indicated that treatment with AMITIZA(R) (lubiprostone) 8 mcg lead to significant relief of overall symptoms of Irritable Bow...

BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients

MILAN, Italy, April 26 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) today announced new data from the E.A.R.L.Y. study (ETV-079), in which treatment of antiviral-naive adult chronic hepatitis B patients with BARACLUDE(R) (entecavir) resulted in greater long-term viral l...

Napo Announces Successful Clinical Results in Phase 2 Study of Crofelemer in Acute Adult Infectious Diarrhea

SOUTH SAN FRANCISCO, Calif., April 10 /PRNewswire/ -- Napo Pharmaceuticals, Inc., (LSE: NAPL and NAPU) is pleased to announce the positive results of a successfully completed Phase 2 trial for CRO-ID (crofelemer for the treatment of acute adult infectious diarrhea) conducted by its partner, Gl...

MAP Pharmaceuticals Reports Positive Results From Phase 2a Clinical Trial of Combination Therapy in Adult Asthmatics

Clinical proof of concept achieved with proprietary drug combination technology MOUNTAIN VIEW, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ), today announced positive results from a Phase 2a clinical study evaluating ...

CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients

Data also showed differences in gastrointestinal and lipid effects between REYATAZ/ritonavir and lopinavir/ritonavir among study population PRINCETON, N.J., Feb. 6 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY ) today announced results from the CASTLE study, in which 300...

New Data Show Unacceptably Low Adult Immunization Rates and That Adults Unaware of Infectious Disease Threat

Experts Urge Integration of Adult Vaccines into Routine Care to Save Lives, Reduce Needless Illness WASHINGTON, Jan. 23 /PRNewswire-USNewswire/ -- New data released today by the Centers for Disease Control and Prevention (CDC) paint a disappointing picture of adult immuniz...

Study Reports Successful Cloning of Human Embryo Using Adult DNA

Key Step Toward Developing Embryonic Stem Cell Lines for Therapeutic Cloning DURHAM, N.C., Jan. 17 /PRNewswire/ -- A California research team has become the first to report, and painstakingly document, the cloning of a human embryo using donated oocytes (egg ce...

Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML

CAMBRIDGE, Mass, Dec. 5 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ ) announced today that the company has completed enrollment of a phase 2 clinical trial examining the safety and effectiveness of Clolar(R) (clofarabine) in previously untreated, older adult patients with acute myel...

Results of VYVANSE(TM) (lisdexamfetamine dimesylate) Pivotal Trial in Adult ADHD Presented at Major Scientific Meeting

All Doses of VYVANSE Studied Demonstrated Significant Efficacy Within One Week of Daily Treatment BOSTON, Oct. 25 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, today announced the results of a stud...

Vion Pharmaceuticals Announces Initiation of a Phase I/II Trial of Cloretazine(R) (VNP40101M) in Combination with Temodar(R) in Adult Brain Tumors

NEW HAVEN, Conn., Sept. 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that an investigator-sponsored trial of its lead anti-cancer agent Cloretazine(R) (VNP40101M) in combination with Temodar(R) (temozolomide) in relapsed or progressive adult malignan...

TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)

TAIPEI, Taiwan, Aug. 10 /Xinhua-PRNewswire/ -- TaiGen Biotechnology Inc. announces the successful completion of patient recruitment for the global double-blind Phase II clinical trial of Nemonoxacin (TG-873870) for the treatment of adult community-acquired pneumonia (CAP). A total of 265 patie...

Newest Adult Stem Therapy Treats Diabetes

Leaves Individuals With Juvenile Diabetes Insulin-Free WASHINGTON, April 10, 2007 /PRNewswire-USNewswire/ -- In yet another advance in adult stem cell therapy, the Journal of the American Medical Association (JAMA) today released a study in which 14 of 15 Juvenile Diabetes patients demonstrated si...

Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease

Adult stem cells cultivated from patients' own blood can potentially improve the quality of life for patients whose lower extremities are affected by peripheral vascular disease, according to a study in China. SHENZHEN, China, July 02, 2007 /PRNewswire/ -- Beike Biotechnology Co., Ltd. (

FDA Issues Complete Response Letter for INTUNIV(TM) (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents

...ractivity disorder, United States, 2003. MMWR. 2005;54(34):842-847. 15. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the national comorbidity survey replication. Am J Psychiatry. 2006; 163:716-723. 16. Annual Estimates o...

Unlikely Treatment Identified by BrainCells Neurogenesis Platform Improved Clinical Outcomes in Patients Suffering From Depression

...s is the process by which pre-existing stem cells in the hippocampus of the adult brain produce new brain cells, including neurons. "Our study result...diseases. Neurogenesis is the process by which endogenous stem cells in the adult human brain produce new brain tissue, including neurons. With its predictiv...

Cryo-Cell Announces C'elle(SM) Research and Development Collaboration with Cryopraxis Cryobiology Ltd.

...omen to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future potential utilization by the donor or possibly first-...omen to collect and cryopreserve menstrual flow containing undifferentiated adult stem cells for future utilization by the donor or possibly their first-degr...

Correction to Earlier Release From Jewish Hospital and University of Louisville

...tical distinction. Louisville researchers and physicians have performed the world's first phase-one FDA-approved clinical trial using "c-kit-positive" adult cardiac stem cells to treat heart disease. The clinical trial is being conducted by a team of University of Louisville physicians at Jewish Hospital, ...

Injection Reverses Heart-Attack Damage

...sponge-like patch, soaked in a compound called periostin that is abundant in the developing fetal heart (and in injured skeletal muscle) but scarce in adult hearts. When the patch was placed over the site of cardiac injury in rats, it induced cardiomyocyte proliferation and improved heart function ( Natur...

Schering-Plough Announces U.S. Filing of Mometasone Furoate/Formoterol Fumarate Combination for the Maintenance Treatment of Asthma

... Inhaled steroids, including ASMANEX, may cause a reduction in growth velocity when administered to pediatric patients. The long-term effect on final adult height is unknown. Health care providers should closely follow the growth of children and adolescents taking corticosteroids by any route, and reduce ...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

...Moapar(R) 11.25mg, the first 3-month injectable formulation, prescribed for a reversible reduction of serum testosterone to the level of castration in adult men suffering from sexual deviations. Developed by Debiopharm, Moapar(R) contains a gonadotropin-releasing hormone (GnRH) agonist analogue. "We...

Swissmedic Grants Debiopharm Marketing Authorisation for Moapar(R), a New Therapeutic Avenue for the Treatment of Sexual Deviations

...Moapar(R) 11.25mg, the first 3-month injectable formulation, prescribed for a reversible reduction of serum testosterone to the level of castration in adult men suffering from sexual deviations. Developed by Debiopharm, Moapar(R) contains a gonadotropin-releasing hormone (GnRH) agonist analogue. "We...

R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023

... a placebo, the tests were conducted on 20 healthy adult males by the following 3 methods and the results w...applied to the vertex region of 6 out of 9 healthy adult males and a placebo to that of the remaining 3 sub...of placebo was applied to 6 and 2 out of 8 healthy adult males respectively. No serious adverse event was o...

Tibotec Pharmaceuticals Announces Agreement to Develop and Commercialize a New Fixed-Dose Combination of TMC278 and Truvada(R) With Gilead Sciences

...ricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) for treatment-naive adult patients with HIV-1. Fixed-dose combinations contain multiple medicines fo... TMC278-C215 are fully recruited having enrolled over 1,300 treatment-naive adult patients with HIV-1. Current HIV treatment guidelines issued by the U.S. De...

Schering-Plough Expands Vicriviroc Phase II Study in Treatment-Naive Patients With HIV

... CCR5 antagonist, for use in first-line therapy of adult treatment-naive HIV-infected patients with R5-type...oll approximately 200 treatment-naive HIV-infected adult patients at more than 35 sites in North America, C...SM, Schechter M, Montaner JS, et al. Treatment for adult HIV infection: 2006 recommendations of the Interna...

Michael J. Fox Foundation Awards Over $2 Million for Validation of 10 Parkinson's Therapeutic Targets

...niversity (Sweden) and Jean-Christophe Rochet, PhD, Purdue University Use of Smo1 a ntagonists to boost endogenous GDNF expression in the adult striatum Andreas H. Kottman, PhD, Columbia University Polo-like kinases as therapeutic targets for Parkinson ' s disease Hilal ...

Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center

...ors. Moreover, in a Phase 2 study conducted at Memorial Sloan-Kettering Cancer Center, perifosine induced responses and delayed disease progression in adult patients with advanced brain tumors. Additionally, combination studies of perifosine with novel agents in patients with advanced brain tumo...

Elbit Imaging Ltd. Announces - Swiss Team Uses InSightec's ExAblate(R) 4000 Brain System to Treat Patients With Functional Brain Disorders

...sibility study testing the use of non-invasive transcranial MR-guided focused ultrasound surgery (TcMRgFUS) for the treatment of neuropathic pain. Ten adult patients diagnosed with chronic neuropathic pain successfully underwent non-invasive deep brain ablation surgery (central lateral thalamotomy) with tr...

Keep Mosquitoes and More Out of Your Yard with Garlic From Garlic Research Labs, Inc.

...tions. Mosquito Barrier is a three pronged attack. First, it kills the adult mosquitoes on contact. Second, the garlic coated plants keep mosquitoes out...osquito Barrier was proven to be effective against both Anopheles and Culex adult mosquitoes. Mosquito Barrier achieved a mortality rate of over 90% after 24...

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

... the treatment of moderate-to-severe, active RA in adult patients when the response to disease-modifying an...te, the treatment of active and progressive PsA in adult patients when the response to previous DMARD thera...ion. The treatment of severe, active AS in adult patients who have responded inadequately to conven...

SUNY Youth Sports Institute Convenes Top Experts in NYC Next Week to Present Research & Analysis on Energy Drink Health Impacts

... Maryland, College Park , MD. One of Dr. Arria's primary research interests is to understand the antecedents and consequences of adolescent and young adult health-risk behaviors. Other noted participants are from recognized institutions like New York Presbyterian Hospital, Mount Sinai Hospital, the...

Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM)

...ACE is being evaluated in the treatment of non-CF patients who have bronchiectasis with Pseudomonas lung infections. In the bronchiectasis trial, 64 adult patients were randomized 2:1 to two doses -- either 280 mg or 560 mg of ARIKACE or placebo for 28 days followed by a 28-day off-treatment observation ...